CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 1,500 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Triple Negative Breast Cancer with ER/PR <10% and HER negative per ASCO/CAP guidelines
  • ✓TNBC stages I-IV
  • ✓TNBC patients within 5 years of diagnosis
  • ✓Germline mutation carriers with deleterious or uncertain mutations in HBOC genes
Key exclusion· 2
  • ✕TNBC patients >5 years from diagnosis
  • ✕Germline carriers with only polymorphisms or favor polymorphisms

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02302742
NCT02302742N/ARecruitingHigh MomentumUpdated 8mo ago
Long Recruiting
CompareCT.gov

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations

University of Kansas Medical Center·observational·Posted Nov 27, 2014·Updated Oct 6, 2025

In Brief

An observational study for Breast Cancer and Hereditary Breast and Ovarian Cancer. Currently recruiting, targeting 1,500 participants across 11 sites.

Signals

Enrolling ahead of pace

Detailed Summary

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Hereditary Breast and Ovarian Cancer
CountriesUnited States
Collaborators--

Timeline

N/ARecruiting
20112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 27, 2014
Enrollment StartMar 22, 2011
Primary CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 15.7 yearsPosted 11.6 years agoPrimary completion in 5 months